Data

LUCID study

The University of Melbourne
Access the data

Licence & Rights

Restrictive Licence

Dataset description

Liberal glUcose Control in critically Ill patients with pre-existing type 2 Diabetes (LUCID): a phase II multicentre randomised controlled trial to evaluate the prevalence and effect of hypoglycaemia. Critically ill patients admitted to ICU with T2DM, demographics, ICU admission details, treatments at enrolment, blood glucose concentrations during admission, insulin administration during admission, ICU, Hospital, day 28 and day 90 outcome data.

Date Information

Created from 2025-03-25
Updated from 2025-03-25
Collected from 2017-05-01/2025-03-23
Click to explore relationships graph

Related Datasets

Subjects

Intensive care
 

Source Study

Trial acronym

LUCID

Trial ID

ACTRN12616001135404

Funding

Charities/Societies/Foundations, Diabetes Australia

Scientific enquiries

A/Prof Adam Deane

Brief Summary

When patients with diabetes are very unwell (critically ill and admitted to ICU) their blood glucose levels are often higher than previously. This frequently requires the use of insulin which is administered directly into a vein. We are uncertain about how aggressively we should treat these blood glucose levels. Currently, patients with diabetes are treated exactly like all other patients, i.e. persons without diabetes, such that insulin is administered when blood glucose reaches 10 mmol/L and t .... Read more

Key Inclusion Criteria

Adult patients (aged 18 years or older). Expected to remain in the ICU until the day after tomorrow. Patient has either an arterial or central line in situ, or the placement of an arterial or central line is imminent (within the next hour) as part of routine ICU management. Patient has type 2 diabetes. The treating clinician believes that that there is a reasonable likelihood that a blood glucose concentration greater than or equal to 10 mmol/L will be recorded at some stage during the ICU admis .... Read more

Key Exclusion Criteria

Death during ICU admission is deemed to be inevitable. Admitted to the ICU for treatment of diabetic ketoacidosis or hyperosmolar state. Patients who have juvenile type 1 diabetes. Requirement for specific blood glucose target as determined by the treating doctor, i.e. the treating clinician believes either intervention or standard care arms of LUCID would not be in the best interests of the patient Patients expected to be eating before the end of the next calendar day. Patients who have previou .... Read more

Can healthy volunteers participate?

No

Population

Sample Size    436

Min. age    18 Years

Max. age    No limit

Sex    Both males and females

Condition category    Critical illness , Type 2 Diabetes

Condition code    Metabolic and Endocrine

Intervention

Intervention code Treatment: Drugs , Treatment: Other

The intervention will be delivered by an ICU nurse, the insulin will be commenced when blood glucose > 14.0 mmol/L and infusion adjusted to target blood glucose 10-14 mmo/L. Concentrations < 10 mmol/L would not be actively treated with glucose. As per the NICE-SUGAR trial each ICU will be able to use the relevant institutional protocol rather than a standardised protocol. Treatment will be for the duration of ICU admission until day 28. Study data will be collected by the sites research nurse an ....
Read more

Comparison

Control group Active

The control will be ‘standard care’ which is the commencement of insulin when blood glucose is > 10.0 mmol/L, with insulin adjusted to target blood concentrations in the range 6-10 mmol/L. Again insulin algorithms will be via local protocol rather than standardised within the study.

Outcomes

Outcome: Incident hypoglycaemia (defined as a blood glucose reading < 4.0 mmol/L) during ICU admission.
Timepoint: During ICU admission up to and including day 28.

Data Dictionary: Not Available

Will individual participant data (IPD) for this trial be available?

yes

What data in particular will be shared?

Individual participant data that underlie the results reported in this trial, after de-identification..

When will data be available?

Beginning 3 months and ending 5 years following article publication..

Available to whom?

Researches who provide a methodologically sound proposal..

Available for what types of analyses?

To achieve aims in the approved proposal..

Source study information is derived from the Australian New Zealand Clinical Trials Registry (ANZCTR). For more information on the ANZCTR, please see anzctr.org.au

How is Heath Data Australia supporting health research?

To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.

Read the guide

How to access data via Health Data Australia

With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.

To start requesting data, simply login with your AAF account.

Learn more